Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Ann Surg Oncol. 2014 Sep 17;22(3):834–842. doi: 10.1245/s10434-014-4042-6

Fig 2.

Fig 2

(A-C) A 57-year-old patient with a single CLM in segments 2-3 and RAS mutation. (A) Before initiation of treatment. (B) Suboptimal radiologic morphologic response after 4 months of preoperative FOLFOX (leucovorin, fluorouracil, and oxaliplatin) with bevacizumab. (C) Minor pathologic response (75% viable tumor cells in CLM) after resection. The patient died of disease 18 months after undergoing a partial left hepatectomy. (D-F) A 68-year-old patient with a single large CLM involving the origin of the right and middle hepatic veins and wild-type RAS. (D) Before initiation of treatment. (E) Optimal morphologic response after 3 months of preoperative FOLFOX with bevacizumab. (F) Major pathologic response (<10% viable tumor cells in CLM) after resection. As of this writing, the patient is alive and disease-free more than 5 years after extended right hepatectomy.